Guidelines for Lp-PLA2 Testing

At present Lp-PLA2 testing is recommended in 4 major guidelines for patients’ estimated to be at moderate or high CVD risk by traditional risk assessment.

Guideline for Management of Dyslipidemia and Prevention of Atherosclerosis by the American Association of Clinical Endocrinologists (2012)

European Guideline on CVD Prevention in Clinical Practice by the European Society of Cardiology (2012)

Guideline for the Primary Prevention of Stroke by the American Heart Association (2011)

Guideline for Cardiovascular Risk in Asymptomatic Adults by the American College of Cardiology Foundation (2010)

Reference Ranges

A recently published study by Feng et al (2014) demonstrated gender-specific differences in reference intervals of serum Lp-PLA2 levels in 763 healthy Chinese Han subjects, with significantly lower serum levels in females compared to males (75th percentile: female
489 U/L (18-49 years) resp. 542 U/L (50-88 years), and males 579 U/L (18-87 years).

The median levels in males and females in this study were similar to the values reported by Winkler er al. In Winkler’s study the 80th percentile was used as reference threshold for a healthy German population of 1702 men aged 34-66 years and 3578 women aged
34-63 years resulting in a reference value of 639 U/L for men and 507 U/L for women.